GURU.Markets stock price, segment price, and overall market index valuation
The company's share price Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biotechnology company focused on treating diseases caused by excessive activation of the complement system. Its stock price reflects the commercial success of its drugs for rare blood and eye diseases.
Share prices of companies in the market segment - Pharma eyes
Apellis is a biotech company focused on treating diseases caused by excessive complement activation. We classify it as a pharmaceutical company (eye diseases), and the chart below reflects general trends in this field.
Broad Market Index - GURU.Markets
Apellis Pharmaceuticals is a biopharmaceutical company developing drugs to treat diseases caused by uncontrolled activation of the complement system. Its focus on innovation makes it a key component of the GURU.Markets index. The chart below represents the entire market. Find out how Apellis compares to it.
Change in the price of a company, segment, and market as a whole per day
APLS - Daily change in the company's share price Apellis Pharmaceuticals
Change_co for Apellis Pharmaceuticals, a biopharmaceutical company, reflects extreme volatility associated with the commercial launch of new drugs. Daily fluctuations indicate sensitivity to sales reports and safety news. This metric is important for biotech risk analysis on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma eyes
Apellis Pharmaceuticals, Inc. is a biotech company. This chart demonstrates the sector's extreme volatility. Comparison with APLS, which focuses on rare disease treatments, helps to assess it as a high-risk, clinical-data-driven asset.
Daily change in the price of a broad market stock, index - GURU.Markets
Apellis Pharmaceuticals is a biopharmaceutical company specializing in drugs for the treatment of rare complement-related diseases. Biotechnology is a volatile sector. The chart below shows average daily fluctuations in this sector, providing context for analyzing Apellis's stock performance.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization Apellis Pharmaceuticals
Apellis is a biotech company specializing in the treatment of eye diseases. Its stock price depends on the success of its products in commercialization and regulatory approvals. These events create unique price movements.
Annual dynamics of market capitalization of the market segment - Pharma eyes
Apellis Pharmaceuticals, Inc. is a commercial biotechnology company focused on developing a new class of drugs for the treatment of rare diseases. Its success depends on the commercialization of its first approved drugs. The chart below shows how the market perceives the potential of its scientific platform.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
Apellis is a biopharmaceutical company whose stock performance is driven by the success of its drug sales and progress in research. The company's business is not dependent on economic cycles. The chart reflects biotech events rather than macroeconomic data, making it a non-cyclical growth story.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization Apellis Pharmaceuticals
Apellis, a biopharmaceutical company focused on treating diseases caused by excessive activation of the complement system, shows the monthly fluctuations in the chart, reflecting the commercial success of its drugs for rare blood and eye diseases.
Monthly dynamics of market capitalization of the market segment - Pharma eyes
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing a new class of drugs targeting the complement system for the treatment of rare diseases. The dynamics of its sector, shown in the chart, reflect high risks. Against this backdrop, it's possible to assess how the commercial launch of its first drugs for blood and eye diseases impacts the company's future.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
Apellis Pharmaceuticals is a biopharmaceutical company focused on treating diseases caused by uncontrolled activation of the complement system. The chart below shows how its stock price has been out of sync with the market, moving in sync with drug approval news and sales data rather than general economic trends.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization Apellis Pharmaceuticals
Shares of Apellis Pharmaceuticals, a company focused on treating rare diseases, are extremely news-sensitive. Weekly price movements reflect the release of clinical trial data, regulatory decisions, and sales reports for approved drugs. The chart below illustrates how short-term events in biotech can cause sharp price fluctuations.
Weekly dynamics of market capitalization of the market segment - Pharma eyes
How unique is Apellis Pharmaceuticals' performance in the biotech sector? This chart compares the company's weekly stock price movements, driven by sales and new research news, with the overall trend. This helps us understand whether a sharp stock move is the result of unique commercial success or a reflection of general sentiment in this volatile industry.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
Apellis Pharmaceuticals develops drugs to treat rare diseases caused by immune system disorders. This chart compares its weekly performance to the market. It shows how disconnected its stock is from macroeconomics and entirely dependent on research progress and regulatory decisions.
Market capitalization of the company, segment and market as a whole
APLS - Market capitalization of the company Apellis Pharmaceuticals
The Apellis Pharmaceuticals valuation chart reflects its scientific platform aimed at treating diseases through the complement system. The company's market cap soared after the approval of its first drugs. The trend shows how investors assess the commercial potential of its innovative drugs for rare diseases.
APLS - Share of the company's market capitalization Apellis Pharmaceuticals within the market segment - Pharma eyes
Apellis Pharmaceuticals focuses on developing drugs to treat diseases caused by uncontrolled activation of the complement system. Its share of its sector market capitalization reflects the breakthrough potential of its technology. The chart shows how the approval and sales of its drugs, such as those for eye diseases, impact its market share.
Market capitalization of the market segment - Pharma eyes
This chart shows the total value of biotech companies focused on treating eye diseases. Apellis Pharmaceuticals is one of the innovators in this field. The dynamics on the chart reflect the enormous hopes and risks associated with developing vision-preserving drugs.
Market capitalization of all companies included in a broad market index - GURU.Markets
The chart below visualizes the market valuation of a scientific approach to treating retinal diseases. Apellis Pharmaceuticals' market capitalization is a bet on its breakthrough research in ophthalmology. The line's dynamics demonstrate how a single successful molecule can generate enormous value and take a significant place in global medicine.
Book value capitalization of the company, segment and market as a whole
APLS - Book value capitalization of the company Apellis Pharmaceuticals
This is an assessment of Apellis Pharmaceuticals' scientific foundation. The chart reflects the value of its intellectual property—patents for innovative drugs, as well as laboratory equipment. The growth of this line is directly linked to progress in clinical trials and the commercialization of drugs targeting rare diseases.
APLS - Share of the company's book capitalization Apellis Pharmaceuticals within the market segment - Pharma eyes
Apellis's tangible assets are not so much its production lines as its advanced R&D centers and laboratories where innovative drugs are developed. The chart shows the company's share of the scientific infrastructure in its niche, reflecting the capital intensity and scale of its research activities in ophthalmology.
Market segment balance sheet capitalization - Pharma eyes
Apellis Pharmaceuticals is a commercial biotech company. It not only develops but also markets its drugs, which requires investment in production and supply chains. This makes it more capital-intensive than an R&D startup. The graph will show whether this model is the norm for the entire biopharmaceutical industry.
Book value of all companies included in the broad market index - GURU.Markets
Apellis Pharmaceuticals' balance sheet represents capital invested in the development and commercialization of drugs for the treatment of rare retinal and blood diseases. The book value chart shows the volume of resources devoted to combating diseases for which there have been no previous effective therapies, reflecting its scientific strength.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - Apellis Pharmaceuticals
Apellis Pharmaceuticals is focused on treating diseases caused by uncontrolled activation of the immune system. Its balance sheet is cash flow for research, and its market capitalization is a valuation of its scientific platform and the commercial potential of its approved drugs. The chart shows how the success of one or two key drugs can generate enormous value.
Market to book capitalization ratio in a market segment - Pharma eyes
Apellis Pharmaceuticals develops drugs to treat rare diseases. The company's primary value lies in its scientific platform and patents. The chart clearly demonstrates how much a market valuation based on the potential of one or two successful drugs can exceed the value of all the company's tangible assets combined.
Market to book capitalization ratio for the market as a whole
Apellis Pharmaceuticals focuses on developing drugs to treat rare diseases. This chart is a clear example of how the market values biotech innovation. Apellis's market capitalization, based on the commercial success of its approved drugs and the potential for future development, far exceeds its modest book value, which consists of labs and offices.
Debts of the company, segment and market as a whole
APLS - Company debts Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biotech company focused on developing drugs to treat rare diseases. The long and expensive clinical trials process requires significant financial resources. This chart shows how the company uses debt to finance its cutting-edge research and drug launches.
Market segment debts - Pharma eyes
Apellis Pharmaceuticals focuses on developing drugs to treat diseases caused by uncontrolled activation of the complement system. This is a cutting-edge area of biopharmaceuticals, requiring significant R&D investment. The chart provides insight into the financial norms of the industry, where companies often use capital to fund multi-year clinical trials.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio Apellis Pharmaceuticals
Apellis Pharmaceuticals focuses on developing drugs to treat rare diseases caused by immune system disorders. Biotech research and drug launch are extremely expensive processes. This chart shows how reliant the company is on external funding, including debt, to support its ambitious research programs.
Market segment debt to market segment book capitalization - Pharma eyes
Apellis Pharmaceuticals specializes in developing drugs to treat rare diseases caused by immune system disorders. This chart compares the company's debt, used to fund expensive research, to the overall market capitalization of its niche pharmaceutical sector. It demonstrates the scale of its scientific bets and financial risks.
Debt to book value of all companies in the market
Apellis Pharmaceuticals develops drugs to treat rare diseases, which requires significant investment. This chart compares the company's debt to the total book value of the entire economy. It shows how significant the company's financial stakes are in its research and development, given its overall size and stock market performance.
P/E of the company, segment and market as a whole
P/E - Apellis Pharmaceuticals
This chart for Apellis Pharmaceuticals, a company developing drugs for rare diseases, shows its market valuation. In the biotech sector, a high valuation without profitability is the norm and reflects investor expectations for the success of its drugs. This metric demonstrates confidence in the scientific and commercial potential of its developments.
P/E of the market segment - Pharma eyes
This metric represents the average valuation for the biotech sector in which Apellis Pharmaceuticals operates. In this industry, which is full of research-stage companies, the average earnings valuation is often uninformative. However, it does reflect the overall level of investor optimism regarding scientific breakthroughs and serves as a benchmark for understanding the company's value.
P/E of the market as a whole
Apellis Pharmaceuticals develops a new class of therapeutic drugs for the treatment of severe diseases caused by uncontrolled activation of the immune system, including in ophthalmology. It is a science-intensive business with high potential. This chart shows how the market as a whole views breakthrough biotech companies.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company Apellis Pharmaceuticals
Apellis Pharmaceuticals is focused on developing drugs to treat diseases caused by uncontrolled activation of the complement system. This chart reflects investor expectations for the commercial success of its drugs, particularly for the treatment of rare eye and blood diseases. It assesses the scientific and market potential of its innovative platform.
%20P%2FE%20Apellis%20Pharmaceuticals&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-Apellis-Pharmaceuticals&v=1772543918516 "Chart of the company's future (projected) P/E Apellis Pharmaceuticals")
Future (projected) P/E of the market segment - Pharma eyes
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing therapeutic compounds to treat diseases by inhibiting the complement system, which plays a role in immunity. The company focuses on ophthalmology and rare diseases. This chart shows overall market sentiment towards the biotech sector, which helps assess Apellis's potential.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-eyes&v=1772543918568 "Future (projected) P/E graph of the market segment - Pharma eyes")
Future (projected) P/E of the market as a whole
Apellis Pharmaceuticals develops innovative drugs targeting the complement system to treat rare eye and blood diseases. This is a story of scientific breakthroughs. The company's valuation is determined not by general market forecasts, but by clinical trial data and the commercial success of its drugs.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772543918602 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biopharmaceutical company focused on developing treatments for diseases caused by overactivation of the immune system. Its financial results depend on the successful commercialization of approved drugs and clinical trial expenditures. This chart shows the balance between sales revenue and significant investments in research and development.
Profit of companies in the market segment - Pharma eyes
Apellis Pharmaceuticals is a commercial biopharmaceutical company focused on developing treatments for diseases caused by excessive complement activation, including in ophthalmology. This chart shows the profitability of its niche segment. The success of its drugs in the market directly influences the profitability of the entire niche, which it largely creates.
Overall market profit
Apellis Pharmaceuticals is focused on developing treatments for rare diseases, particularly in ophthalmology. The company's success depends on the effectiveness of its drugs and regulatory approvals, not on the overall economic health. This corporate earnings chart illustrates the macroeconomic backdrop against which biotech innovations like Apellis's are creating their own growth story.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company Apellis Pharmaceuticals
Apellis Pharmaceuticals specializes in developing drugs to treat diseases caused by uncontrolled activation of the complement system, including rare eye and blood diseases. This chart reflects analysts' expectations for future profits, which depend on sales volumes of its currently approved drugs and the success of clinical trials of new candidates in its pipeline.
%20profit%20of%20the%20company%20Apellis%20Pharmaceuticals&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-Apellis-Pharmaceuticals&v=1772543918724 "Graph of future (projected) profit of the company Apellis Pharmaceuticals")
Future (predicted) profit of companies in the market segment - Pharma eyes
Apellis Pharmaceuticals focuses on developing therapeutic compounds for the treatment of autoimmune and inflammatory diseases, particularly through complement inhibition. This chart shows profitability forecasts for the ophthalmology pharmaceutical segment. It reflects expectations for the launch of new drugs for the treatment of complex eye diseases.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-eyes&v=1772543918746 "Graph of future (predicted) profits of companies in a market segment - Pharma eyes")
Future (predicted) profit of the market as a whole
Apellis Pharmaceuticals is developing therapies for rare diseases caused by overactivation of the immune system. The company's success depends on the results of clinical trials. However, the overall profit forecast, reflected in this chart, is influencing investor sentiment. A positive outlook facilitates raising capital to fund expensive research and bring the drugs to market.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772543918774 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - Apellis Pharmaceuticals
Apellis Pharmaceuticals is a commercial biopharmaceutical company focused on treating rare diseases. With its already launched products, the P/S ratio is becoming a key indicator of success. It reflects how investors view the sales growth dynamics of its drugs and whether they believe they have the potential to become blockbusters in the market.
P/S market segment - Pharma eyes
Apellis Pharmaceuticals specializes in developing drugs to treat diseases caused by uncontrolled activation of the complement system, particularly in ophthalmology. The success of their first drug has created a strong revenue base. The chart shows how investors view the potential of this drug and other developments compared to similar companies in the sector.
P/S of the market as a whole
Apellis Pharmaceuticals focuses on developing drugs to treat diseases caused by uncontrolled activation of the immune system, particularly in ophthalmology. Revenue depends on the successful commercialization of its products. This chart helps understand the premium the market is willing to pay for the revenue of innovative biotech companies with breakthrough technologies.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company Apellis Pharmaceuticals
Apellis Pharmaceuticals develops drugs to treat rare diseases caused by uncontrolled activation of the immune system. Its valuation depends on the success of its key drugs. This chart shows investor expectations for future sales based on the potential of its drugs for eye and blood diseases.
%20P%2FS%20Apellis%20Pharmaceuticals&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-Apellis-Pharmaceuticals&v=1772543918828 "The graph of the company's future (projected) P/S Apellis Pharmaceuticals")
Future (projected) P/S of the market segment - Pharma eyes
Apellis Pharmaceuticals focuses on developing therapeutics for the treatment of diseases through complement inhibition, including ophthalmology and rare diseases. This chart shows how the market assesses the future commercial success of its innovative drugs compared to other pharmaceutical companies, reflecting confidence in its scientific platform.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-eyes&v=1772543918834 "Future (projected) P/S market segment graph - Pharma eyes")
Future (projected) P/S of the market as a whole
Apellis Pharmaceuticals develops drugs to treat rare diseases caused by immune system disorders. The company's success depends on the approval and adoption of its innovative therapies. This chart shows overall investor revenue forecasts, and Apellis illustrates how the biotech sector, with its high growth potential, influences overall investor optimism.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772543918855 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales Apellis Pharmaceuticals
Apellis Pharmaceuticals is a commercial biopharmaceutical company focused on developing drugs to treat diseases by inhibiting the complement system. The chart shows revenue from sales of its approved drugs. Sales growth is directly dependent on the successful launch of these drugs, their acceptance by the medical community, and the expansion of their indications.
Sales of companies in the market segment - Pharma eyes
Apellis Pharmaceuticals specializes in treating diseases caused by uncontrolled activation of the complement system. This chart shows the revenue from its key drugs, allowing investors to assess which drugs contribute most to sales. This provides insight into the commercial success of its research and development efforts.
Overall market sales
Apellis Pharmaceuticals specializes in developing drugs to treat rare diseases, particularly in ophthalmology. Like many biotech companies, its success depends on clinical trial results and regulatory approval. This market overview chart does not reflect Apellis' key growth drivers, which lie in innovation.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company Apellis Pharmaceuticals
The revenue forecast for Apellis Pharmaceuticals, which focuses on treating diseases caused by immune system disorders, is critically important. It reflects analysts' expectations for the sales of its drugs, particularly those for rare eye and blood diseases. This chart demonstrates Wall Street's confidence in the commercial success of its innovative therapies.
%20sales%20of%20the%20company%20Apellis%20Pharmaceuticals&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-Apellis-Pharmaceuticals&v=1772543919136 "Schedule of future (projected) sales of the company Apellis Pharmaceuticals")
Future (projected) sales of companies in the market segment - Pharma eyes
Apellis Pharmaceuticals is focused on developing drugs to treat diseases caused by uncontrolled activation of the complement system. This chart shows projected revenue for the ophthalmology pharmaceutical segment. It allows one to assess the growth potential of this market, which is critical to the commercial success of Apellis's products.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-eyes&v=1772543919164 "Schedule of future (projected) sales of companies in the market segment - Pharma eyes")
Future (projected) sales of the market as a whole
Apellis Pharmaceuticals specializes in developing drugs to treat diseases caused by excessive complement activation, including rare eye diseases. The overall economic conditions shown in the graph impact the solvency of healthcare systems and the investment climate, which is important for funding further research and product commercialization.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772543919223 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biotechnology company focused on developing drugs for rare diseases. This graph shows the path from scientific discovery to commercial success. The company's ability to convert revenue into profit is directly dependent on the successful sales of its drugs and the efficient management of its extensive research and development costs.
Market segment marginality - Pharma eyes
Apellis Pharmaceuticals specializes in developing drugs to treat rare diseases caused by excessive complement activation. This chart illustrates the commercial potential of its breakthrough research. High profitability after product launch will indicate strong demand and high value for its medicines.
Market marginality as a whole
Apellis Pharmaceuticals focuses on treating diseases by controlling the complement system of the immune system. This is a cutting-edge field of biomedicine. This chart reflects average market profitability, while Apellis strives to create an entirely new therapeutic niche where the success of a single drug can lead to explosive growth and ultra-high margins.
Employees in the company, segment and market as a whole
Number of employees in the company Apellis Pharmaceuticals
Apellis Pharmaceuticals is a biopharmaceutical company focused on treating diseases through complement inhibition. The growth of its team, particularly in sales and marketing, is a direct result of the approval of key drugs and their successful commercial launches, as demonstrated by this chart.
Share of the company's employees Apellis Pharmaceuticals within the market segment - Pharma eyes
Apellis Pharmaceuticals is a biopharmaceutical company focused on treating diseases through complement inhibition. This chart demonstrates its scientific clout in its niche. It demonstrates the proportion of leading immunologists and researchers specializing in this complex area of biology that Apellis brings together to develop breakthrough treatments.
Number of employees in the market segment - Pharma eyes
Apellis Pharmaceuticals specializes in developing drugs to treat diseases caused by uncontrolled activation of the complement system. This chart shows the company's presence in the narrow niche of ophthalmic pharmaceuticals. The growing number of specialists here indicates breakthroughs in the treatment of rare eye and blood diseases, a key area for Apellis.
Number of employees in the market as a whole
Apellis Pharmaceuticals develops therapeutic drugs for rare diseases. Its growing staff of scientists and clinical researchers reflects advances in biotechnology and the investment it has made in breakthrough medical research. This represents a contribution to a knowledge-intensive sector that creates high-value jobs.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals is a commercial biotechnology company whose drugs target rare diseases. Their value comes from their existing pipeline and promising developments. This chart shows their high intellectual capital. The value of the patents and scientific discoveries created by their team of scientists is distributed among a relatively small staff.
%20of%20the%20company%20Apellis%20Pharmaceuticals%20(APLS)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-Apellis-Pharmaceuticals-APLS&v=1772543919649 "Chart of market capitalization per employee (in thousands of dollars) of the company Apellis Pharmaceuticals (APLS)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma eyes
Apellis is a commercial biotech company that has achieved success with its drugs (for example, Syfovre for eye treatment). It is no longer just an R&D project, but a company with sales. This chart shows the industry average. It helps assess how the market perceives its commercial success and the potential of its scientific platform per employee.
%20by%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-eyes&v=1772543919664 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma eyes")
Market capitalization per employee (in thousands of dollars) for the overall market
Apellis Pharmaceuticals focuses on developing drugs to treat diseases caused by overactivation of the immune system. The company's entire value lies in its scientific research and patents. This chart demonstrates the high regard in which each scientist is valued, as their work has the potential to lead to the creation of a blockbuster drug capable of generating billions of dollars.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772543919682 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals is a biotech company focused on treating diseases through complement inhibition. The company already has approved drugs. This chart shows the transition from R&D losses to profitability: how successfully the sales and marketing team brings complex, expensive drugs to market, generating profit per employee.
%20Chart%20Apellis%20Pharmaceuticals%20(APLS)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-Apellis-Pharmaceuticals-APLS&v=1772543919721 "Company Profit Per Employee (in thousands of dollars) Chart Apellis Pharmaceuticals (APLS)")
Profit per employee (in thousands of dollars) in the market segment - Pharma eyes
Apellis Pharmaceuticals is a biotech company with approved drugs for rare diseases (including eye diseases). This chart shows the benchmark for "Specialty Pharma." In this R&D sector, the benchmark is either negative (at the R&D stage) or astronomically high (when a blockbuster drug is approved).
%20in%20the%20market%20segment%20-%20Pharma%20eyes&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-eyes&v=1772543919758 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma eyes")
Profit per employee (in thousands of dollars) for the market as a whole
Apellis is a biopharmaceutical company specializing in the treatment of eye diseases (geographical atrophy) and blood diseases. It has a complex R&D operation. This chart, which shows the average market profitability per employee, poses the question: how does the biotech sector, where Apellis operates and where a single breakthrough can be worth billions, compare to average profitability?
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772543919807 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals, a biopharmaceutical company focused on rare diseases, demonstrates the transition from research to sales in this chart. After a drug is launched, revenue per employee increases sharply, reflecting the high cost of innovative drugs and the ability of a small commercial team to operate in a specialized market.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-Apellis-Pharmaceuticals-APLS&v=1772543919818 "Sales chart per company employee Apellis Pharmaceuticals (APLS)")
Sales per employee in the market segment - Pharma eyes
Apellis Pharmaceuticals is a commercial biotech company focused on rare diseases and ophthalmology. Unlike R&D startups, Apellis already generates revenue. This chart shows the average revenue per employee in the segment. It allows you to assess how productive Apellis's commercial and scientific teams are compared to its competitors.
Sales per employee for the market as a whole
Apellis Pharmaceuticals focuses on treating rare diseases (such as eye diseases). The company already has approved drugs and is generating revenue. This chart shows how successfully their commercial team is selling these highly specialized and expensive medications. The growth in this indicator suggests that market demand for their therapies is outpacing staff growth.
Short shares by company, segment and market as a whole
Shares shorted by company Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals achieved success with its drug for a rare blood disorder and has now launched it for the treatment of age-related macular degeneration (an eye disease). This chart shows doubts about the launch's success. Bears may bet the drug won't gain widespread adoption due to side effects or strong competition.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-Apellis-Pharmaceuticals-APLS&v=1772543919977 "Short Shares Chart for the Company Apellis Pharmaceuticals (APLS)")
Shares shorted by market segment - Pharma eyes
Apellis Pharmaceuticals focuses on developing drugs to treat diseases caused by uncontrolled activation of the complement system (affecting vision and blood). This chart highlights the pessimism in the pharmaceutical sector. The increase in short positions in the industry may indicate that investors are concerned about competition or problems with reimbursement for expensive innovative drugs.
Shares shorted by the overall market
Apellis Pharmaceuticals (APLS) is a commercial biotech company focused on treating rare diseases, particularly in ophthalmology. This chart highlights the overall market fears. Although APLS has an approved product, investors may be concerned that a recession (which the market fears) will put downward pressure on the prices of expensive drugs for rare diseases.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator Apellis Pharmaceuticals (APLS)
Apellis Pharmaceuticals focuses on drugs for rare diseases (complement system). The stock is volatile and dependent on R&D. This chart for APLS can soar above 70 on positive trial data or approvals. A range below 30 is often associated with failures or safety concerns.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-Apellis-Pharmaceuticals-APLS&v=1772543920198 "RSI 14 indicator chart for the company's stock Apellis Pharmaceuticals (APLS)")
RSI 14 Market Segment - Pharma eyes
Apellis Pharmaceuticals specializes in treating complement-related diseases (part of the immune system), particularly rare blood disorders and geographic atrophy (vision loss). This chart measures the overall excitement and decline in the ophthalmic biotech sector. It helps differentiate APELLIS's clinical data-driven movement from the overall industry trend.
RSI 14 for the overall market
Apellis Pharmaceuticals (APLS), a biotech company, depends on R&D funding, as reflected in this chart. During periods of market euphoria, investors are willing to invest in risky but breakthrough research. In times of panic, risk appetite vanishes, and companies burning through cash risk running out of funds.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast APLS (Apellis Pharmaceuticals)
Apellis Pharmaceuticals is focused on developing drugs to treat diseases caused by uncontrolled activation of the complement system (part of the immune system). This chart shows the average analyst forecast. Their targets are based on the successful commercial launch of already approved drugs and the results of clinical trials of new candidates in this complex area.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-APLS-Apellis-Pharmaceuticals&v=1772543920368 "A chart showing analyst consensus forecasts for the expected stock price. APLS (Apellis Pharmaceuticals)")
The difference between the consensus estimate and the actual stock price APLS (Apellis Pharmaceuticals)
Apellis Pharmaceuticals is a biotech company that achieved a breakthrough with Syfovre, the world's first treatment for geographic atrophy (a cause of blindness). However, the launch was marred by safety concerns. This chart shows how analysts weigh the enormous market potential against these commercial risks. It reflects the gap between the target price and the current price.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-APLS-Apellis-Pharmaceuticals&v=1772543920416 "A chart showing the difference between the consensus forecast and the actual stock price. APLS (Apellis Pharmaceuticals)")
Analyst consensus forecast for stock prices by market segment - Pharma eyes
Apellis is a biotech company specializing in the complex complement system (part of the immune system). Its breakthrough is a drug for the treatment of dry macular degeneration. This chart shows analysts' overall expectations across the sector, reflecting whether experts believe in the success of new eye treatments.
Analysts' consensus forecast for the overall market share price
Apellis (APLS) is a biotech company focused on treating diseases through complement inhibition. Their breakthrough drug treats a rare blood disorder (PNH) and retinal degeneration. This chart shows the overall risk appetite, reflecting the market's willingness to fund expensive and disruptive treatments.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index Apellis Pharmaceuticals
Apellis is a biotech company focused on treating rare diseases by inhibiting the complement system (part of the immune system). Their success lies in their eye (Syfovre) and blood (Empaveli) drugs. This chart is a summary indicator of their launches. It likely reflects the sales growth rate of their new, breakthrough drugs and the confidence in their R&D platform.
AKIMA Market Segment Index - Pharma eyes
Apellis Pharma is a biotech pioneer in the emerging field of complement inhibition (C3). The company has launched drugs for rare blood diseases (PNH) and eye diseases (GA). This summary metric evaluates R&D. The graph shows the average value for the segment. This benchmark: how does Apellis' breakthrough (C3) R&D platform differentiate it from the average pharma company?
The AKIM Index for the overall market
Apellis is a commercial-stage biotech focused on rare blood diseases and, more importantly, eye diseases (geographic atrophy). It's a high-risk scientific bet. This chart, which reflects the market average, provides a macro backdrop. It helps assess how this innovative story stacks up against broader economic trends.
